Loading…
Delivering nanomedicines to patients: A practical guide
Abstract This is a perspective on the current state of development of nanomedicines in Europe. The view is expressed that a much higher translational success rate could be achieved, with rewards for all stakeholders, if researchers understood the industrial decision points required for new drugs. Ge...
Saved in:
Published in: | Nanomedicine 2015-05, Vol.11 (4), p.983-992 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c521t-ef5a07efc5e132f44f81c4e9abedcb44563901c3646585dfec6cf3e4b5e73dd53 |
---|---|
cites | cdi_FETCH-LOGICAL-c521t-ef5a07efc5e132f44f81c4e9abedcb44563901c3646585dfec6cf3e4b5e73dd53 |
container_end_page | 992 |
container_issue | 4 |
container_start_page | 983 |
container_title | Nanomedicine |
container_volume | 11 |
creator | Eaton, Mike A.W., PhD Levy, Laurent, PhD Fontaine, Olivier M.A., MSc |
description | Abstract This is a perspective on the current state of development of nanomedicines in Europe. The view is expressed that a much higher translational success rate could be achieved, with rewards for all stakeholders, if researchers understood the industrial decision points required for new drugs. Getting a drug through the clinic will not help patients unless it is developable by industry. This article is written in the hope that it will help researchers and SMEs to decide where they are in the established process, whether they are making progress and to determine what to do next. It attempts to map the early stages from ideation to first (time) in man (FIM). From the Clinical Editor The field of nanomedicine has come a long way in the past decade. The overall dream of any researcher in this field remains the realization of concept to clinical product. In this paper, the authors outlined for the readers, the underlying problems and actions that need to be done, so that current challenges can be solved. |
doi_str_mv | 10.1016/j.nano.2015.02.004 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1682890141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1549963415000507</els_id><sourcerecordid>1682890141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-ef5a07efc5e132f44f81c4e9abedcb44563901c3646585dfec6cf3e4b5e73dd53</originalsourceid><addsrcrecordid>eNp9kTtPwzAUhS0EoqXwBxhQRpaE61fSIIRUladUiQGYLde5qVzSpNhJpf57HLV0YGCyh3M-6XyXkEsKCQWa3iyTWtdNwoDKBFgCII7IkEqRx3kq2PHhz8WAnHm_BOAZQH5KBkxmTOQsH5LsASu7QWfrRdTTVlhYY2v0UdtEa91arFt_G02itdOmtUZX0aKzBZ6Tk1JXHi_274h8Pj1-TF_i2dvz63Qyi41ktI2xlBoyLI1EylkpRDmmRmCu51iYuRAy5TlQw1ORyrEsSjSpKTmKucSMF4XkI3K9465d892hb9XKeoNVpWtsOq9oOmbjgBA0RNkualzjvcNSrZ1dabdVFFQvTC1VP1H1whQwFYSF0tWe383D9kPl11AI3O0CGFZuLDrlTZBigieHplVFY__n3_-pm8rWvccv3KJfNp2rgz9FlQ8F9d6frL8YlQAgIeM_JN6RAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1682890141</pqid></control><display><type>article</type><title>Delivering nanomedicines to patients: A practical guide</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Eaton, Mike A.W., PhD ; Levy, Laurent, PhD ; Fontaine, Olivier M.A., MSc</creator><creatorcontrib>Eaton, Mike A.W., PhD ; Levy, Laurent, PhD ; Fontaine, Olivier M.A., MSc</creatorcontrib><description>Abstract This is a perspective on the current state of development of nanomedicines in Europe. The view is expressed that a much higher translational success rate could be achieved, with rewards for all stakeholders, if researchers understood the industrial decision points required for new drugs. Getting a drug through the clinic will not help patients unless it is developable by industry. This article is written in the hope that it will help researchers and SMEs to decide where they are in the established process, whether they are making progress and to determine what to do next. It attempts to map the early stages from ideation to first (time) in man (FIM). From the Clinical Editor The field of nanomedicine has come a long way in the past decade. The overall dream of any researcher in this field remains the realization of concept to clinical product. In this paper, the authors outlined for the readers, the underlying problems and actions that need to be done, so that current challenges can be solved.</description><identifier>ISSN: 1549-9634</identifier><identifier>EISSN: 1549-9642</identifier><identifier>DOI: 10.1016/j.nano.2015.02.004</identifier><identifier>PMID: 25724929</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Commercialize ; Delivery of Health Care - methods ; Delivery of Health Care - trends ; Development ; Europe ; Humans ; Internal Medicine ; Milestones ; Nanomedicine - methods ; Nanomedicine - trends ; Translation ; TRL</subject><ispartof>Nanomedicine, 2015-05, Vol.11 (4), p.983-992</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-ef5a07efc5e132f44f81c4e9abedcb44563901c3646585dfec6cf3e4b5e73dd53</citedby><cites>FETCH-LOGICAL-c521t-ef5a07efc5e132f44f81c4e9abedcb44563901c3646585dfec6cf3e4b5e73dd53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25724929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eaton, Mike A.W., PhD</creatorcontrib><creatorcontrib>Levy, Laurent, PhD</creatorcontrib><creatorcontrib>Fontaine, Olivier M.A., MSc</creatorcontrib><title>Delivering nanomedicines to patients: A practical guide</title><title>Nanomedicine</title><addtitle>Nanomedicine</addtitle><description>Abstract This is a perspective on the current state of development of nanomedicines in Europe. The view is expressed that a much higher translational success rate could be achieved, with rewards for all stakeholders, if researchers understood the industrial decision points required for new drugs. Getting a drug through the clinic will not help patients unless it is developable by industry. This article is written in the hope that it will help researchers and SMEs to decide where they are in the established process, whether they are making progress and to determine what to do next. It attempts to map the early stages from ideation to first (time) in man (FIM). From the Clinical Editor The field of nanomedicine has come a long way in the past decade. The overall dream of any researcher in this field remains the realization of concept to clinical product. In this paper, the authors outlined for the readers, the underlying problems and actions that need to be done, so that current challenges can be solved.</description><subject>Commercialize</subject><subject>Delivery of Health Care - methods</subject><subject>Delivery of Health Care - trends</subject><subject>Development</subject><subject>Europe</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Milestones</subject><subject>Nanomedicine - methods</subject><subject>Nanomedicine - trends</subject><subject>Translation</subject><subject>TRL</subject><issn>1549-9634</issn><issn>1549-9642</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kTtPwzAUhS0EoqXwBxhQRpaE61fSIIRUladUiQGYLde5qVzSpNhJpf57HLV0YGCyh3M-6XyXkEsKCQWa3iyTWtdNwoDKBFgCII7IkEqRx3kq2PHhz8WAnHm_BOAZQH5KBkxmTOQsH5LsASu7QWfrRdTTVlhYY2v0UdtEa91arFt_G02itdOmtUZX0aKzBZ6Tk1JXHi_274h8Pj1-TF_i2dvz63Qyi41ktI2xlBoyLI1EylkpRDmmRmCu51iYuRAy5TlQw1ORyrEsSjSpKTmKucSMF4XkI3K9465d892hb9XKeoNVpWtsOq9oOmbjgBA0RNkualzjvcNSrZ1dabdVFFQvTC1VP1H1whQwFYSF0tWe383D9kPl11AI3O0CGFZuLDrlTZBigieHplVFY__n3_-pm8rWvccv3KJfNp2rgz9FlQ8F9d6frL8YlQAgIeM_JN6RAA</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>Eaton, Mike A.W., PhD</creator><creator>Levy, Laurent, PhD</creator><creator>Fontaine, Olivier M.A., MSc</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150501</creationdate><title>Delivering nanomedicines to patients: A practical guide</title><author>Eaton, Mike A.W., PhD ; Levy, Laurent, PhD ; Fontaine, Olivier M.A., MSc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-ef5a07efc5e132f44f81c4e9abedcb44563901c3646585dfec6cf3e4b5e73dd53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Commercialize</topic><topic>Delivery of Health Care - methods</topic><topic>Delivery of Health Care - trends</topic><topic>Development</topic><topic>Europe</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Milestones</topic><topic>Nanomedicine - methods</topic><topic>Nanomedicine - trends</topic><topic>Translation</topic><topic>TRL</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eaton, Mike A.W., PhD</creatorcontrib><creatorcontrib>Levy, Laurent, PhD</creatorcontrib><creatorcontrib>Fontaine, Olivier M.A., MSc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nanomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eaton, Mike A.W., PhD</au><au>Levy, Laurent, PhD</au><au>Fontaine, Olivier M.A., MSc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Delivering nanomedicines to patients: A practical guide</atitle><jtitle>Nanomedicine</jtitle><addtitle>Nanomedicine</addtitle><date>2015-05-01</date><risdate>2015</risdate><volume>11</volume><issue>4</issue><spage>983</spage><epage>992</epage><pages>983-992</pages><issn>1549-9634</issn><eissn>1549-9642</eissn><abstract>Abstract This is a perspective on the current state of development of nanomedicines in Europe. The view is expressed that a much higher translational success rate could be achieved, with rewards for all stakeholders, if researchers understood the industrial decision points required for new drugs. Getting a drug through the clinic will not help patients unless it is developable by industry. This article is written in the hope that it will help researchers and SMEs to decide where they are in the established process, whether they are making progress and to determine what to do next. It attempts to map the early stages from ideation to first (time) in man (FIM). From the Clinical Editor The field of nanomedicine has come a long way in the past decade. The overall dream of any researcher in this field remains the realization of concept to clinical product. In this paper, the authors outlined for the readers, the underlying problems and actions that need to be done, so that current challenges can be solved.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25724929</pmid><doi>10.1016/j.nano.2015.02.004</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1549-9634 |
ispartof | Nanomedicine, 2015-05, Vol.11 (4), p.983-992 |
issn | 1549-9634 1549-9642 |
language | eng |
recordid | cdi_proquest_miscellaneous_1682890141 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Commercialize Delivery of Health Care - methods Delivery of Health Care - trends Development Europe Humans Internal Medicine Milestones Nanomedicine - methods Nanomedicine - trends Translation TRL |
title | Delivering nanomedicines to patients: A practical guide |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A13%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Delivering%20nanomedicines%20to%20patients:%20A%20practical%20guide&rft.jtitle=Nanomedicine&rft.au=Eaton,%20Mike%20A.W.,%20PhD&rft.date=2015-05-01&rft.volume=11&rft.issue=4&rft.spage=983&rft.epage=992&rft.pages=983-992&rft.issn=1549-9634&rft.eissn=1549-9642&rft_id=info:doi/10.1016/j.nano.2015.02.004&rft_dat=%3Cproquest_cross%3E1682890141%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c521t-ef5a07efc5e132f44f81c4e9abedcb44563901c3646585dfec6cf3e4b5e73dd53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1682890141&rft_id=info:pmid/25724929&rfr_iscdi=true |